MedPath
Found 20 clinical trials|View Analysis
Sort by:

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

Phase 1
Not yet recruiting
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
First Affiliated Hospital of Chongqing Medical University
Target Recruit Count
18
Registration Number
NCT06766266

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Phase 2
Not yet recruiting
Conditions
Non-Muscle Invasive Bladder Carcinoma
Recurrent Bladder Carcinoma
Recurrent Non-Muscle Invasive Bladder Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 1 Bladder Cancer AJCC v8
First Posted Date
2024-12-13
Last Posted Date
2024-12-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
344
Registration Number
NCT06733363
Locations
🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1
Not yet recruiting
Conditions
Non-Muscle Invasive Bladder Carcinoma
Stage 0 Gallbladder Cancer AJCC V8
Stage I Bladder Cancer AJCC V8
Interventions
Biological: BCG Solution
Procedure: Cystoscopy
Drug: Docetaxel
Drug: Gemcitabine
Other: Home Health Encounter
Drug: Mitomycin
Other: Questionnaire Administration
First Posted Date
2024-11-26
Last Posted Date
2024-12-27
Lead Sponsor
Mayo Clinic
Target Recruit Count
40
Registration Number
NCT06704191
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2
Recruiting
Conditions
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
First Posted Date
2024-08-09
Last Posted Date
2024-11-14
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT06545955
Locations
🇺🇸

Ferring Investigational Site, Los Angeles, California, United States

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Phase 2
Recruiting
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma
Non-muscle Invasive Bladder Cancer
Interventions
First Posted Date
2024-07-16
Last Posted Date
2024-12-17
Lead Sponsor
John Sfakianos
Target Recruit Count
60
Registration Number
NCT06503614
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Active, not recruiting
Conditions
Urothelial Carcinoma
Non-Muscle Invasive Bladder Urothelial Carcinoma
Muscle Invasive Bladder Urothelial Carcinoma
First Posted Date
2024-05-02
Last Posted Date
2024-08-23
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
92
Registration Number
NCT06396533
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Phase 1
Recruiting
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma
Stage 0is Bladder Cancer AJCC v8
Stage 0a Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Interventions
Drug: PLZ4-coated paclitaxel loaded micelles (PPM)
First Posted Date
2023-12-15
Last Posted Date
2024-12-18
Lead Sponsor
Mamta Parikh
Target Recruit Count
12
Registration Number
NCT06173349
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Recruiting
Conditions
Non-Muscle Invasive Bladder Neoplasms
Bladder Urothelial Carcinoma
Bladder Cancer
Bladder Neoplasm
Non-Muscle Invasive Bladder Urothelial Carcinoma
Bladder Disease
Bladder Cancer Stage I, With Cancer in Situ
Bladder Cancer Recurrent
Bladder Urothelial Carcinoma in Situ
Non Muscle Invasive Bladder Cancer
First Posted Date
2023-12-12
Last Posted Date
2023-12-12
Lead Sponsor
IRCCS San Raffaele
Target Recruit Count
20000
Registration Number
NCT06167356
Locations
🇮🇹

IRCCS Ospedale San Raffaele, Milan, MI, Italy

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Completed
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma
Non Muscle Invasive Bladder Cancer
Interventions
Diagnostic Test: Bladder EpiCheck
First Posted Date
2023-09-01
Last Posted Date
2023-09-07
Lead Sponsor
Nucleix Ltd.
Target Recruit Count
168
Registration Number
NCT06020807
Locations
🇺🇸

Urology San Antonio, San Antonio, Texas, United States

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Phase 4
Not yet recruiting
Conditions
Non-muscle-invasive Bladder Cancer
Non-Muscle Invasive Bladder Urothelial Carcinoma
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
First Posted Date
2023-07-27
Last Posted Date
2024-03-22
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
258
Registration Number
NCT05962541
© Copyright 2025. All Rights Reserved by MedPath